Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis.

ABSTRACT:

Background

It is unclear whether continuing anti-fibrotic therapy until the time of lung transplant increases the risk of complications in patients with idiopathic pulmonary fibrosis.

Objectives

To investigate whether the time between discontinuation of anti-fibrotic therapy and lung transplant in patients with idiopathic pulmonary fibrosis affects the risk of complications.

Methods

We assessed intra-operative and post-transplant complications among patients with idiopathic pulmonary fibrosis who underwent lung transplant and had been treated with nintedanib or pirfenidone continuously for ⩾ 90 days at listing. Patients were grouped according to whether they had a shorter (⩽ 5 medication half-lives) or longer (> 5 medication half-lives) time between discontinuation of

SUBMITTER: Astor TL 

PROVIDER: S-EPMC10126649 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature